Catamnestic observation in children after Sars-Cov-2- associated multisystem inflammatory syndrome

Existing data on the follow-up of children with SARS-CoV-2-associated Multisystem Inflammatory Syndrome are limited.

The purpose of this study. To investigate the medium and long-term consequences of Multisystem Inflammatory Syndrome in children who had Multisystem Inflammatory Syndrome associated with SARS-CoV-2.

Methods and materials. A retrospective study was conducted that included 93 children with a history of SARS-CoV-2-associated Multisystem Inflammatory Syndrome. The analysis included monitoring the health status of the study group of children using data from the Damumed medical information system. Identified changes were categorized into the following periods: occurring within the first 6 months, 1 year, 2 years, and more than 2 years post-illness.

Results: Diseases identified during outpatient monitoring in the follow-up included pneumonia (9.6 %), vegetative-vascular dystonia (11.8 %), vision deterioration (7.5 %), joint damage (6.6 %), metabolic disorders (2.2 %), and recurrence of Multisystem Inflammatory Syndrome (2.2 %). Cardiovascular system assessment revealed changes unusual for the acute period of MIS: regression of symptoms of the inflammatory process of the heart in the form of cardiomegaly, left ventricular dysfunction, pericarditis, pulmonary arterial hypertension, coronary artery disease, mitral regurgitation, and an increase in valvular disease of the right heart chambers (regurgitation of the pulmonary and tricuspid valves), arrhythmias compared to the acute period (p<0.005). These changes were predominantly observed during the first year of follow-up.

Conclusions: Children who had Multisystem Inflammatory Syndrome associated with SARSCoV-2 exhibited various somatic disorders during long-term monitoring. The majority of patients (64.1 %) continued to have subclinical signs of myocardial damage within the first year of observation.

1. Noval Rivas, M., Porritt, R. A., Cheng, M. H. et al. (2022). Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis. Frontiers in Immunology, 13. DOI: 10.3389/fimmu.2022.941009.

2. Das, N., Hill, R., Trivedi, M. et al. (2022). Longitudinal Assessment of Cardiac Function Following Multisystem Inflammatory Syndrome in Children Associated with COVID-19. Pediatric Cardiology. DOI: 10.1007/s00246-022-02972-3.

3. Sezer, M., Çelikel, E., Tekin Z. E. et al. (2022). Multisystem inflammatory syndrome in children: clinical presentation, management, and short- and long-term outcomes. Clinical Rheumatology, 41(12), 3807-3816. DOI: 10.1007/s10067-022-06350-5.

4. Lin, J., Harahsheh, A. S., Raghuveer, G. et al. (2023). Emerging Insights into the Pathophysiology of Multi-system Inflammatory Syndrome in Children Associated with COVID-19. Canadian Journal of Cardiology. DOI: 10.1016/j.cjca.2023.01.002.

5. Patel, J. M. (2022). Multisystem Inflammatory Syndrome in Children (MIS-C). Current Allergy and Asthma Reports, 22(5), 53-60. DOI: 10.1007/s11882-022-01031-4.

6. Tong, T., Yao, X., Lin, Z. et al. (2022). Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. Pediatric Rheumatology, 20(1), 112. DOI: 10.1186/s12969-022-00771-x.

7. Jaxybayeva, I., Boranbayeva, R., Abdrakhmanova, S. et al. (2022). Comparative analysis of clinical and laboratory data in children with multisystem inflammatory syndrome associated with SARS-CoV-2 in the Republic of Kazakhstan. Mediterranean Journal of Hematology and Infectious Diseases, 14(1), 2022064. DOI: 10.4084/MJHID.2022.064.

8. Irfan, O., Muttalib, F., Tang, K. et al. (2021). Clinical characteristics, treatment and outcomes of paediatric COVID-19: A systematic review and metaanalysis. Archives of Disease in Childhood, 106(5), 440-448. DOI: 10.1136/archdischild-2020-321385.

9. Penner, J., Abdel-Mannan, O., Grant, K. et al. (2021). 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. The Lancet Child & Adolescent Health, 5(7), 473- 482. DOI: 10.1016/S2352-4642(21)00138-3.

10. Pawar, R. S., Tarkasband, V. A., Patil, R. K., Naik, A. V. (2021). Second Episode of Multisystem Inflammatory Syndrome in Children. Pediatric Infectious Disease Journal, 40(11), 452-452. DOI: 10.1097/INF.0000000000003249.

11. Chakraborty, J. N., Johnson, J., Spagnoli, et al. (2022). Long-Term Cardiovascular Outcomes of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 Using an InstitutionBased Algorithm. Pediatric Cardiology. DOI: 10.1007/s00246-022-03020-w.

12. Capone, C. A., Misra, N., Ganigara, M. et al. (2021). Six-Month Follow-up of Patients With Multi-System Inflammatory Syndrome in Children. Pediatrics, 148(4).

13. Sperotto, F., Friedman, K. G., Son, M. B. F. et al. (2021). Cardiac manifestations in SARS-CoV2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. European Journal of Pediatrics, 180(2), 307-322. DOI: 10.1542/peds.2021-050973.

14. Valverde, Y., Singh, J., Sanchez-de-Toledo et al. (2021). Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation, 143(1), 21-32. DOI: 10.1161/CIRCULATIONAHA.120.050065.